Close Menu

NEW YORK (GenomeWeb) – BioFire Defense, a BioMérieux company, has been granted Emergency Use Authorization by the US Food and Drug Administration for BioThreat-E, a commercially available Ebola molecular diagnostic test for use in CLIA moderate- and high-complexity laboratories.

In addition, the firm's NGDS BT-E assay, which is intended for use in US Department of Defense laboratories, also received EUA. Both tests run on the PCR-based FilmArray platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.